ALXN stock news

Alexion Pharmaceuticals reached a deal to acquire Achillion for $930 million. The stocks were moving in opposite directions. Read more
Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
Is (ALXN) Outperforming Other Medical Stocks This Year? Read more
Alexion Pharmaceuticals Inc on Wednesday agreed to buy small biotech Achillion Pharmaceuticals Inc in a deal initially valued at $930 million, a move that will help the company retain its dominance in treating rare blood disorders. Read more
Shares of Achillion Pharmaceuticals Inc. rocketed 82% in premarket trading Wednesday, after the biopharmaceutical company agreed to be acquired by Alexion… Read more
Alexion Pharmaceuticals Inc on Wednesday agreed to buy small biotech Achillion Pharmaceuticals Inc in a $930 million deal, to boost its pipeline of rare disease treatments. Alexion's offer of $6.30 per share represents a premium of 72.6% to Achillion stock's close on Tuesday. Read more
Alexion (ALXN) teams up with Stealth BioTherapeutics for a late-stage therapy for mitochondrial diseases. Read more
Alexion (ALXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Read more
Let's take a look at the factors, which make Alexion (ALXN) a hot target for a takeover amid the M&A wave in the pharma/biotech sector. Read more
Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. Read more
Stocks closed mixed on Thursday as the US and China restarted deputy-level trade talks after a nearly two-month stalemate. A Chinese delegation of about 30 officials meet with Trump administration officials to establish the groundwork for high-level talks in October. Investors also weighed the Federal Reserve's decision to inject another $75 billion into financial markets in an effort to keep interest rates from going higher. Visit the Business Insider homepage for more stories . Stocks finished mixed on Thursday as the US and China kicked-off deputy level trade negotiations for the first time in close to two months. A Chinese delegation of about 30 officials met with members from the Office of the United States Trade Representative in Washington, D.C. on Thursday morning to establish the groundwork for high-level talks set to take place in October. The reengagement also comes a few short weeks after both the US and China eased tensions by delaying and alleviating some tariffs. Traders are keeping a close eye on the talks for any sign that the two countries could come closer to forging a resolution to the year-long trade war. Read more
Alexion's (ALXN) shares decline, following the news of the departure of its current chief financial officer, Paul Clancy. Read more
Alexion (ALXN) strengthens its amyloidosis portfolio with an exclusive license secured from Eidos to develop and commercialize an investigational small molecule AG10 in Japan. Read more
Alexion Pharmaceuticals (ALXN) and Elanco Animal Health (ELAN) have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration…..ALXN Read more
Alphabet, H&R Block, and Alexion Pharmaceuticals are among Tuesday’s stocks to watch, following the holiday weekend. Read more

Proudly made at

ROCKIT